YUCAIPA, Calif., April 27, 2010 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Pink Sheets:IGNT), a medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S. and $8 billion globally, today announced the following letter to shareholders from CEO and Chairman of the Board, Scott R. Sand:
"Ingen is on the verge of tremendous growth after enduring a number of regulatory and economic obstacles. In the face of economic headwinds, the company obtained both FDA and ISO Certification and launched several new and inspiring medical products in the respiratory market. As a result of this success, we have attracted many investors and new shareholders.
Ingen has developed a global perspective on the markets in which we compete. First, we conducted a thorough market study for our products with InTouch Life Science Corporation, while at the same time filing patents and trademarks for our proprietary technology; second, we properly registered our products with the FDA and qualified the products for FDA export; third, we hired Emergo Group, a recognized global consulting firm that assisted us with the ISO 13485 Certification, CE Mark and distribution partners in order to comply with the world markets for distribution of our medical products; and finally, we hired KGMA Business Solutions, a leading consulting firm to prepare and file our GSA Contract, as well as develop government contracts with the VA Hospitals and Department of Defense. More important, we have lowered our production costs for our products, increased our margins and the margins of our distributors, while keeping a competitive edge on pricing our products in the challenging medical markets of today.
This company has integrated growth partnership services into all your departments, divisions, and project teams. With 100 percent integration, the full benefits and value from teamwork, improved decision-making, and creativity will be realized. We have developed a growth culture which at first was an enormous challenge, and now has resulted as a clear vision, developing growth teams, opening communication, expanding an attitude of empowerment and leadership by example, pushing our various teams, raising the bar, and setting goals as a part of our role in leadership.
Ingen has made changes to foster a growth culture with a clear vision for the future. With these successes and changes, the company has undergone a restructuring in order to align our incentives with that of our shareholders. The company is now keenly focused on growth, open communication, and leadership by example, as it works diligently to expand its sales and deliver shareholder value.
Investing in our growth is a nominal expense to ensure that Ingen is working to maximize the growth potential of this company. With our past accomplishments of benchmarking our goals, we have learned that extraordinary companies have extraordinary goals. The company is presently strong and the future indicates strong potential.
Ingen has started 2010 on a solid footing by achieving all of its goals and expects to end the year with $11 million in sales. Morevoer, we have taken steps to significantly reduce our debt with our note holders and anticipate a share buy-back program in June. By virtually every measure we have met or exceeded our objectives and positioned the company for a strong finish in 2010, as well as a sound future for the years to come.
Our inspiration comes from many sources - our shareholders, customers and consumers, as well as our critics. Our staff and consulting team have a passion for what they do that ignites this inspiration every day, everywhere we do business. We remain fresh, relevant and original by knowing what to change without changing what we know. We are asking more questions, listening more closely, and collaborating more effectively with our partners, OEMs, the GPO, as well as distribution and strategic consultants to give our customers the product they need, and provide our shareholders with the results that they deserve."
http://www.smartnasalcannula.com/
http://www.ingenpulseoximeter.com/
About Ingen:
Ingen is an ISO Certified medical device manufacturer with an emerging new medical product line for the respiratory market worth an estimated $4 billion in the U.S., and $8 billion globally. The company introduced Oxyview into the respiratory market in late 2007 after securing U.S. and Foreign Patents and a successful registration with the Food & Drug Administration. The company is establishing domestic and global distribution with manufacture representative organizations, and OEM partners. In 2009 the SMART Nasal Cannula using Oxyview Technology was introduced as the world's first oxygen cannula with an in-line pneumatic oxygen flow meter. In 2010 the company introduced its new INGEN Pulse Oximeter. The Oxyview product line is available to the home care markets, commercial medical markets, aviation, automotive, and government sources. The company is licensed with the Department of Health and Human Services, and manufactures its products in the State of California. With approximately 32 million U.S. patients with Chronic Obstructive Pulmonary Disease (COPD), and 600 million patients worldwide, Ingen Technologies is now the largest manufacturer of in-line gravity-independent oxygen flow meters.
The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472
Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.